Eisai invests US$63.5M in cold-chain pharma packaging hub at Hatfield for enhanced EMEA supply

UK – Eisai has invested approximately £48 million (US$63.5 million) at its Hatfield, UK manufacturing site to build cold-chain packaging and supply capabilities for temperature-controlled medicines, transitioning from external contract packaging to an in-house model serving Europe, the Middle East and Africa.

The project, supported by the UK Government’s Life Sciences Innovative Manufacturing Fund and subject to terms and conditions, will expand the Hatfield facility’s operations beyond traditional oral solid dose manufacturing to support packaging and supply of temperature-controlled medicines for injection and infusion. 

The phased expansion includes construction of ambient and cold-chain warehouses, expansion of goods receipt and dispatch functions, and installation of new packaging buildings and packaging lines. 

The site’s advanced production flexibility, capacity for multilingual and small-batch packaging, and robust quality management systems will support Eisai’s global supply network.

How Cold-Chain Warehousing and Advanced Packaging Lines Support EMEA Pharmaceutical Distribution

The Hatfield site will serve as a manufacturing hub for multiple regions, including Europe, the Middle East and Africa. 

The LSIMF, launched in 2024 and backed by £520 million (US$699 million) from the UK government, was established to strengthen domestic life sciences manufacturing and improve preparedness for future health emergencies. 

Haruo Naito, CEO at Eisai, stated that the strategic investment reflected the company’s long-term commitment to strengthening resilient supply capabilities for innovative medicines and pipeline products while further deepening its long-standing relationship with the UK. 

He added that Eisai valued the opportunity to work with the UK government in strengthening life sciences manufacturing and healthcare resilience for the future.

What Transition to In-House Packaging Means for Pharma Supply Chain Resilience

The investment aligns with the UK government’s policy to strengthen domestic pharmaceutical manufacturing. 

Lord Vallance, Minister of State for Science, said that building world-class manufacturing capabilities in the UK would secure the supply of vital medicines that could transform lives. 

He noted that Eisai’s government-backed investment would support the creation of new skilled jobs in Hatfield and was another example of the benefits of international companies investing in the UK, bolstering the country’s reputation as a life sciences hub while growing the economy. 

The expansion will allow Eisai to bring more packaging operations in-house, reducing reliance on third-party contractors and improving supply stability and flexibility. 

The project is being implemented in multiple phases, with completion expected by the 2027 financial year. The Hatfield site aims to enhance its role in Eisai’s global supply network through advanced production flexibility and robust quality management systems.

Subscribe to our email newsletters that provide busy executives like you with the latest news insights and trends from Africa and the World. SUBSCRIBE HERE